Committee Members
Past Committee Members
FENS Structure
FENS is governed by a Council. Each member society has one vote in the Council. >>

.: Bezard, Erwan

Publication Committee Member

Erwan Bezard
UMR CNRS 5227 "Mouvment-Adaption-Cognition"
Bât 3B - ler étage
146 rue Léo Saignat
33076 Bordeaux cedex
France
Phone: +33 557 571 687
Fax: +33 556 901 421
Mobil: +33 675 603 717
E-mail: erwan.bezard@u-bordeaux2.fr

Curriculum Vitae

Research interests

Parkinson disease; basal ganglia; physiology; functional anatomy; behaviour; experimental therapeutics

Education

1995
DEA, University of Bordeaux 2 (Bordeaux, France)
1998
PhD, University of Bordeaux 2 (Bordeaux, France)
1999-2001
Post-Doc, University of Manchester (Manchester, UK)
2003
Habilitation, University of Bordeaux 2 (Bordeaux, France)

Current Position

INSERM Research Director (DR2), Laboratoire "Mouvement-Adaptation-Cognition", CNRS UMR 5227, Université de Bordeaux 2, France.
Co-director of the "French Bank of Cells and Tissus from Primates" (J.L. Nahon, Nice)
Leader of the reseach group: Pathophysiology of parkinsonian syndromes (n=23)
Physiopathologie des syndromes parkinsoniens
Research Delegate, Agence Evaluation de la Recherche et de l’Enseignement Supérieur

Other occupations

Since 2000
Director, Plénitudes Sarl (Consulting in management), France.
Since 2003
Director, Motac Neuroscience (Contract research organization), UK.
Since 2004
Director, Motac Cognition (Contract research organization), USA/UK.
Since 2006
Visiting Professor, China Academy of Medical Sciences, Beijing, China.
Since 2007
Collegium of Professors, Neurosciences PhD program, Tor Vergata University, Roma, Italy.

Consulting and expertise

Since 2001
Drug Development Expert for Movement Disorders in several drug companies.
Since 2001
Expert for Movement Disorders at Motac Neuroscience (UK).
Since 2003
Member of grant review committees at the Michael J. Fox Foundation (USA).
Since 2005
Member of scientific advisory board at the Michael J. Fox Foundation (USA).
Since 2007
Member of executive scientific advisory board at the Michael J. Fox Foundation (USA).
Since 2004
Member of Synapse Editorial Board
Since 2004
Member of Neurobiology of Disease Editorial Board
Since 2006
Associate Editor of Neurobiology of Disease
2006
Editor of the book "Recent Breakthroughs in basal Ganglia Research", Nova Pub., USA
Since 2007
Member of Targeted Proteins database (Dopamine receptors section) Editorial Board
Since 2008
Member of Movement Disorders Editorial Board
Since 2008
Member of Neurological Research Editorial Board
Since 2008
Member of Current Neuropharmacology Editorial Board
Since 2009
Member of the FENS publication committee

Professional Memberships

1996-present
Member, Societe des Neurosciences (France)
1996-present
Member, Federation of European Neuroscience Societies
1996-present
Member, Society For Neuroscience (USA)
1999-present
Member, Club des Ganglions de la Base (France)
2002-present
Member, Movement Disorders Society (USA).
2003-present
Member, American Association for the Advancement of Science (USA).
2004-present
Member, International Basal Ganglia Society
2005-present
Member of the DopaNet network

Key bibliometric numbers (Isi Web of Knowledge - as of 13 January 2009)

Publications: 101
Total number of citations: 2255
Mean citation per publication: 22.3
H factor: 27

Selected Publications

  • A. Nadjar, C. Gerfen and E. Bezard. Priming for L-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Progress in Neurobiology 2009, 87: 1-9
  • A. Muñoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Björklund, E. Bezard# and Manolo Carta#. Serotonin autoreceptor agonists for the treatment of L-dopa-induced dyskinesia. Brain (in press) (Co-last author + corresponding)
  • B. Scholz, M. Svensson, H. Alm, K. Sköld, K. Kultima, C. Guigoni, E. Doudnikoff, Q. Li, A. R. Crossman, E. Bezard and Per E Andrén. Striatal proteomic analysis sugests that first L-dopa dose equates to chronic exposure: does priming exist? PLoS ONE 3(2): e1589. doi:10.1371/journal.pone.0001589 (co-last author)
  • S. Schuster, A. Nadjar, J.T. Guo, Q. li, C. Ittrich, B. Hengerer and E. Bezard. The HMG-CoA Reductase Inhibitor Lovastatin reduces severity of L-dopa-induced abnormal involuntary movements in experimental Parkinson’s disease. Journal of Neuroscience 2008, 28: 4311-4316
  • S. Schuster, E. Doudnikoff, D. Rylander, A. Berthet, I. Aubert, C. Ittrich, B. Bloch, M.A. Cenci, D.J. Surmeier, B. Hengerer and E. Bezard. Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-DOPA-induced dyskinesia. Biological Psychiatry (in press)
  • S.J. Gold, C.V. Hoang, B.W. Potts, G. Porras, E. Pioli, K.W. Kim, A. Nadjar, C. Qin, G.J. LaHoste, Q. Li, B.H. Bioulac, J.L. Waugh, E. Gurevich, R.L. Neve and E. Bezard. RGS9-2 negatively modulates L-dopa-induced dyskinesia in experimental Parkinson’s disease. Journal of Neuroscience 2007, 27 : 14338-14348.
  • P. Belujon, E. Bezard, A. Taupignon, B.H. Bioulac and A. Benazzouz. Noradrenergic modulation of subthalamic nucleus activity: behavioural and electrophysiological evidence in intact and 6-hydroxydopamine lesioned rats. Journal of Neuroscience 2007, 27: 9595-9606.
  • S. Guo, T. Yang, X. Yang, E. Bezard and B. Zhao. Protective effect of green tea polyphenols on rat model of Parkinson’s disease caused by 6-OHDA through ROS-NO pathway. Biological Psychiatry 2007, 62:1353-1362.
  • B. Pasquereau, A. Nadjar, D. Arkadir, E. Bezard, B.H. Bioulac, C.E. Gross and T. Boraud. Shaping of motor responses by incentive values through the basal ganglia. Journal of Neuroscience 2007, 27: 1176-1183.
  • AHV Schapira, E Bezard, J Brotchie, F Calon, G L Collingridge, B. Ferger, B.Hengerer, E Hirsch, P Jenner, N Le Novere, JA Obeso, M A Schwarzschild, U. Spampinato and G Davidai,. Novel pharmacological targets for the treatment of Parkinson’s disease. Nature Drug Reviews 2006, 5: 845-854.
  • A. Nadjar, J.M. Brotchie, C. Guigoni, Q. Li, S.B. Zhou, G.J. Wang, P. Ravenscroft, F. Georges, A.R. Crossman, and E. Bezard. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic non-human primates: a call for a reappraisal of the functional organization of the basal ganglia. Journal of Neuroscience 2006, 26: 8653-8661.
  • I. Aubert*, C. Guigoni*, Q. Li, S. Dovero, B. H. Bioulac, A.R. Crossman, C. E. Gross, B. Bloch and E. Bezard. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-dopa-induced dyskinesia. Biological Psychiatry 2007, 61: 836-844.
  • C. Guigoni, L. Qin, I. Aubert, S. Dovero, B. H. Bioulac, B. Bloch, A.R. Crossman, C. E. Gross and E. Bezard. Involvement of sensorimotor, limbic, and associative basal ganglia domains in levodopa-induced dyskinesia. Journal of Neuroscience 2005, 25: 2102-2107.
  • I. Aubert, C. Guigoni, L. Qin, S. Dovero, K. Hakansson, N. Barthe, B. H. Bioulac, C. E. Gross, G. Fisone, B. Bloch and E. Bezard. Increased D1 dopamine receptor signalling in levodopa-induced dyskinesia. Annals of Neurology 2005, 57: 17-26.
  • X. Yu-Xiang, E. Bezard, Z. Bao-Lu. Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. Journal of Biological Chemistry 2005, 280: 32405-32412.
  • W. Meissner, M. Hill, F. Tison, C. E. Gross and E. Bezard. Neuroprotective strategies for Parkinson’s disease: conceptual limits of clinical trials and animal models. Trends in Pharmacological Sciences 2004, 25: 249-253.
  • E. Bezard, S. Ferry, U. Mach, H. Stark, L. Leriche, T. Boraud, C.E. Gross and P. Sokoloff. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine 2003, 9: 762-767.
  • E. Bezard, C. Gross and J. M. Brotchie. Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends in Neuroscience 2003, 26: 215-221.
  • E. Bezard. Neuroprotection for Parkinson’s disease: call for clinically driven experimental. Lancet Neurology 2003, 2: 393.
  • E. Bezard, J. Baufreton, G. Owens, A. R. Crossman, H. Dudek, A. Taupignon and J. M. Brotchie. Sonic Hedgehog is a neuromodulator in the adult basal ganglia. FASEB Journal 2003, 10.1096, fj.03-0291fje.
  • M. Marvanova, J. Menager, E. Bezard, R.E. Bontrop, L. Pradier and G. Wong. Microarray (comparative genomic) analysis of non human primates : validation of experimental models in neurological disorders. FASEB Journal 2003, 10.1096/fj.02-0681fje.
  • C.H. Tai, T. Boraud, E. Bezard, B. Bioulac, C.E. Gross and A. Benazzouz. Electrophysiological and Metabolic Evidence that High Frequency Stimulation of the Subthalamic Nucleus Bridles Neuronal Activity in the Subthalamic Nucleus and the Substantia Nigra Reticulata. FASEB Journal 2003, 17: 1820-1830.
  • E. Bezard, S. Dovero, D. Belin, S. Duconger, V. Jackson-Lewis, S. Przedborski, P. V Piazza, C.E. Gross and M. Jaber. Enriched environment confers resistance to MPTP and cocaine: involvement of dopamine transporter and neurotrophic factors. Journal of Neuroscience 2003, 23: 10999-11007
  • T. Boraud, E. Bezard, B. Bioulac and C. Gross. From single extracellular unit recording in experimental and human parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Progress in Neurobiology 2002, 66: 265-283.
  • E. Bezard, J. M. Brotchie and C. Gross. Pathophysiology of levodopa-induced dyskinesias: Potential for new therapies. Nature Reviews Neuroscience 2001, 2: 577-588.
  • E. Bezard, A.R. Crossman, C. Gross and J.M. Brotchie. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. FASEB Journal 2001, 10.1096/fj.00-0637fje.
  • E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, D. Guilloteau, A.R. Crossman, B. Bioulac J.M. Brotchie, and C. Gross. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson’s disease. Journal of Neuroscience 2001, 21:6853-6861.
  • T. Boraud, E. Bezard, B. Bioulac and C. Gross. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurons in the MPTP-treated monkey. Brain 2001, 124: 546-557.